Loading...
Publication
Utilização e incorporação de cannabis e/ou seus componentes em formulações farmacêuticas
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| Projeto de pós-graduação_42201 | 1.43 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
A utilização terapêutica da planta Cannabis sativa L. remonta há mais de 5000 anos, tendo sido considerada como uma das plantas fundamentais na medicina tradicional. Com a evolução da ciência e do conhecimento, a utilização de produtos obtidos a partir desta planta deixou de ser relevante e passou a ser proibida, existindo apenas na sociedade como uma forma de droga de abuso. Nas últimas décadas, o mundo ocidental recuperou o interesse científico e terapêutico na canábis e seus derivados/componentes e incorporou-os na prática clínica. Em 1988, foi descoberto o recetor canabinoide do tipo 1 no cérebro e, em 1992, o primeiro endocanabinoide, a anandamida. Estas duas descobertas foram importantes para reforçar o interesse científico e terapêutico da planta Cannabis sativa L.
Em Portugal, o uso desta planta ou de partes dela, ou mesmo dos seus extratos (e.g., o óleo extraído e canabinoides), para fins medicinais está permitido desde junho de 2018 e, noutros países, como o Canadá, desde 2001. O Canadá foi o primeiro país a cultivar a canábis para fins medicinais e a permitir a sua utilização terapêutica.
Em Portugal, a prescrição de produtos à base da planta de canábis para fins medicinais é feita mediante receita médica especial, estando reservada aos casos em que se determine que os tratamentos convencionais autorizados não estão a produzir os efeitos esperados ou provocam efeitos adversos de relevância, e a sua dispensa é exclusiva a farmácias.
The therapeutic use of the Cannabis sativa L. plant dates back over 5000 years, having been regarded as one of the fundamental plants in traditional medicine. With the evolution of science and knowledge, the use of products derived from this plant ceased to be relevant and became prohibited, existing only in society as a form of drug abuse. In recent decades, the Western world has regained scientific and therapeutic interest in cannabis and its derivatives/components, incorporating them into clinical practice. In 1988, the type 1 cannabinoid receptor was discovered in the brain, and in 1992, the first endocannabinoid, anandamide, was identified. These two discoveries were important in reinforcing the scientific and therapeutic interest in the Cannabis sativa L. plant. In Portugal, the use of this plant or parts of it, or even its extracts (e.g., the extracted oil and cannabinoids), for medicinal purposes has been allowed since June 2018, and in other countries, such as Canada, since 2001. Canada was the first country to cultivate cannabis for medicinal purposes and to allow its therapeutic use. In Portugal, the prescription of cannabis-based products for medicinal purposes is done through a special medical prescription, reserved for cases where it is determined that authorized conventional treatments are not producing the expected effects or are causing significant adverse effects, and its dispensation is exclusive to pharmacies.
The therapeutic use of the Cannabis sativa L. plant dates back over 5000 years, having been regarded as one of the fundamental plants in traditional medicine. With the evolution of science and knowledge, the use of products derived from this plant ceased to be relevant and became prohibited, existing only in society as a form of drug abuse. In recent decades, the Western world has regained scientific and therapeutic interest in cannabis and its derivatives/components, incorporating them into clinical practice. In 1988, the type 1 cannabinoid receptor was discovered in the brain, and in 1992, the first endocannabinoid, anandamide, was identified. These two discoveries were important in reinforcing the scientific and therapeutic interest in the Cannabis sativa L. plant. In Portugal, the use of this plant or parts of it, or even its extracts (e.g., the extracted oil and cannabinoids), for medicinal purposes has been allowed since June 2018, and in other countries, such as Canada, since 2001. Canada was the first country to cultivate cannabis for medicinal purposes and to allow its therapeutic use. In Portugal, the prescription of cannabis-based products for medicinal purposes is done through a special medical prescription, reserved for cases where it is determined that authorized conventional treatments are not producing the expected effects or are causing significant adverse effects, and its dispensation is exclusive to pharmacies.
Description
Keywords
Canábis Formulação Desenvolvimento farmacêutico Canabinoides Canabidiol Terpenos Cetrahidrocanabinol Cannabis Formulation Pharmaceutical development Cannabinoids Cannabidiol Terpenes Tetrahydrocannabinol